Key result
In nondiabetic patients with STEMI, high HbA1c (>5.8%) was associated with higher 12-month mortality (7.7% vs 2.7%, p=0.043) and increased 1-year rehospitalization (19.0% vs 8.8%, p=0.016).
Why the study?
Does a higher HbA1c level (>5.8%) associate with increased severity of CAD and worse 1-year outcomes in nondiabetic patients with STEMI?
Population
290 nondiabetic patients with acute ST-elevation myocardial infarction (STEMI)
Comparison
High HbA1c level (>5.8%) vs Low HbA1c level (⩽5.8%)
Design
Cohort
Follow-up
1 year
Authors
Loading...
Elevated HbA1c associated with CAD severity in diabetes; leaves open whether tighter control improves post-MI outcomes.
Cohort (n=290)
Does a higher HbA1c level (>5.8%) associate with increased severity of CAD and worse 1-year outcomes in nondiabetic patients with STEMI?
Absolute Event Rate: 7.7% vs 2.7%
p-value: p=0.043
In nondiabetic patients with STEMI, an HbA1c level >5.8% is associated with more severe coronary artery disease, higher 1-year mortality, and increased hospital readmission rates.
Ghaffari et al. (2015) conducted a cohort in acute ST-elevation myocardial infarction (STEMI) (n=290). High HbA1c (>5.8%) vs. Low HbA1c (⩽5.8%) was evaluated on 12-month mortality (p=0.043). In nondiabetic patients with STEMI, high HbA1c (>5.8%) was associated with higher 12-month mortality (7.7% vs 2.7%, p=0.043) and increased 1-year rehospitalization (19.0% vs 8.8%, p=0.016).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: